These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9709939)

  • 1. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group.
    Orme SM; McNally RJ; Cartwright RA; Belchetz PE
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2730-4. PubMed ID: 9709939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of benign and malignant tumors in patients with acromegaly at a single institute.
    Kurimoto M; Fukuda I; Hizuka N; Takano K
    Endocr J; 2008 Mar; 55(1):67-71. PubMed ID: 18202526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased incidence of neoplasia in females with acromegaly.
    Cheung NW; Boyages SC
    Clin Endocrinol (Oxf); 1997 Sep; 47(3):323-7. PubMed ID: 9373454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.
    Ayuk J; Clayton RN; Holder G; Sheppard MC; Stewart PM; Bates AS
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1613-7. PubMed ID: 15070920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of malignant tumors in patients with acromegaly.
    Higuchi Y; Saeki N; Iuchi T; Uchino Y; Tatsuno I; Uchida D; Tanaka T; Noguchi Y; Nakamura S; Yasuda T; Yamaura A; Sunami K; Oka Y; Uozumi A
    Endocr J; 2000 Mar; 47 Suppl():S57-60. PubMed ID: 10890185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does acromegaly enhance mortality?
    Ayuk J; Sheppard MC
    Rev Endocr Metab Disord; 2008 Mar; 9(1):33-9. PubMed ID: 18075787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homocysteine levels in acromegaly patients.
    Hekimsoy Z; Ozmen B; Ulusoy S
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature.
    Dal J; Leisner MZ; Hermansen K; Farkas DK; Bengtsen M; Kistorp C; Nielsen EH; Andersen M; Feldt-Rasmussen U; Dekkers OM; Sørensen HT; Jørgensen JOL
    J Clin Endocrinol Metab; 2018 Jun; 103(6):2182-2188. PubMed ID: 29590449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nationwide survey of mortality in acromegaly.
    Kauppinen-Mäkelin R; Sane T; Reunanen A; Välimäki MJ; Niskanen L; Markkanen H; Löyttyniemi E; Ebeling T; Jaatinen P; Laine H; Nuutila P; Salmela P; Salmi J; Stenman UH; Viikari J; Voutilainen E
    J Clin Endocrinol Metab; 2005 Jul; 90(7):4081-6. PubMed ID: 15886256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACTH deficiency, higher doses of hydrocortisone replacement, and radiotherapy are independent predictors of mortality in patients with acromegaly.
    Sherlock M; Reulen RC; Alonso AA; Ayuk J; Clayton RN; Sheppard MC; Hawkins MM; Bates AS; Stewart PM
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4216-23. PubMed ID: 19808848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GH and mortality in acromegaly.
    Sheppard MC
    J Endocrinol Invest; 2005; 28(11 Suppl International):75-7. PubMed ID: 16625851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excess mortality in acromegaly.
    Holdaway IM
    Horm Res; 2007; 68 Suppl 5():166-72. PubMed ID: 18174739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer incidence and cause-specific mortality in male and female physicians: a cohort study in Estonia.
    Innos K; Rahu K; Baburin A; Rahu M
    Scand J Public Health; 2002; 30(2):133-40. PubMed ID: 12028862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
    Swearingen B; Barker FG; Katznelson L; Biller BM; Grinspoon S; Klibanski A; Moayeri N; Black PM; Zervas NT
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3419-26. PubMed ID: 9768641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cancer incidence and mortality study of Dow Chemical Canada Inc. manufacturing sites.
    Burns C; Harrison K; Jammer B; Zuccarini D; Lafrance B
    Occup Med (Lond); 2005 Dec; 55(8):618-24. PubMed ID: 16174663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing mortality in acromegaly.
    Holdaway IM; Rajasoorya RC; Gamble GD
    J Clin Endocrinol Metab; 2004 Feb; 89(2):667-74. PubMed ID: 14764779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benign and malignant tumors in patients with acromegaly.
    Barzilay J; Heatley GJ; Cushing GW
    Arch Intern Med; 1991 Aug; 151(8):1629-32. PubMed ID: 1678593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment outcomes and mortality of 94 patients with acromegaly.
    Trepp R; Stettler C; Zwahlen M; Seiler R; Diem P; Christ ER
    Acta Neurochir (Wien); 2005 Mar; 147(3):243-51; discussion 250-1. PubMed ID: 15627919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.